Merrill reiterates New River Pharma at buy

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at a buy rating and a $43 target price following the company's two-for-one stock split. New River said it plans multiple drug-development programs this year, including NRP104 for attention deficit hyperactivity disorder and NPR290 for acute pain. Shares of the Radford, Va., pharmaceutical company were up 11 cents, or 0.37%, at $29.59 on volume of 216,783 shares versus the three-month running average of 228,971 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.